Transcriptional regulation of lipid metabolism by fatty acids: A key determinant of pancreatic β-cell function

Nutrition and Metabolism

Volumn 2, Issue , 2005, Pages

  Fatehi Hassanabad, Zahra ^a   Chan, Catherine B ^a  

^a UNIVERSITY OF PRINCE EDWARD ISLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FAT; FATTY ACID; GLUCOSE; INSULIN; LIPID; LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRANSCRIPTION FACTOR;

ADIPOCYTE; CALORIC INTAKE; CELL FUNCTION; CHOLESTEROL METABOLISM; CONCENTRATION (PARAMETERS); DIABETES MELLITUS; DISEASE COURSE; ENVIRONMENTAL FACTOR; FATTY ACID METABOLISM; GENE FUNCTION; GENETIC ANALYSIS; GENOMICS; GLUCOSE HOMEOSTASIS; HEALTH; HEMOCONCENTRATION; HORMONE ACTION; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIPID METABOLISM; LIPID STORAGE; LIPOLYSIS; LIPOPROTEIN METABOLISM; MASS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PROTEIN ANALYSIS; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SPECIES COMPARISON; TISSUE; TRANSCRIPTION REGULATION;

EID: 15444366638     PISSN: 17437075     EISSN: None     Source Type: Journal    
DOI: 10.1186/1743-7075-2-1     Document Type: Review

References (160)

1. Kutchai HC: Digestion and absorption. In In Principles of Physiology Edited by: Berne RM, Levy MN. Toronto: Mosby Company; 1990:410-414.
2. Oxidation of fatty acids. In In Principles of Biochemistry 2nd edition. Edited by: Lehninger AL, Nelson DL, Cox MM. New York: Worth Publishers Inc; 1997:479-497.
3. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
4. Centers for Disease Control and Prevention: National Diabetes Fact Sheet: National estimate and general information on diabetes in the United States, 2000 Atlanta: US Department of Health and Human Services; 2003.
5. Defronzo RA: The triumvirate: beta cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988, 37:667-687.
6. Burke JP, Williams K, Gaskill SP, Hazuda HP, Haffner SM, Stern MP: Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study. Arch Intern Med 1999, 159:1450-1456.
7. Ludvik B, Nolan JJ, Baloga J, Sacks D, Olefsky J: Effect of obesity on insulin resistance in normal subjects and patients with NIDDM. Diabetes 1995, 44:1121-1125.
8. Fraze E, Donner CC, Swislocki AL, Chiou YA, Chen YD, Reaven GM: Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrinol Metab 1985, 61:807-811.
9. McGarry JD: What if Minkowski had been ageusic? An alternative angle on diabetes. Science 1992, 258:766-770.
10. Malaisse WJ, Best L, Kawazu S, Malaisse-Lagae F, Sener A: The stimulus-secretion coupling of glucose-induced insulin release: fuel metabolism in islet deprived of exogenous nutrient. Arch Biochem Biophys 1983, 224:102-110.
11. Hellerstrom C: Effects of carbohydrates on the oxygen consumption of isolated pancreatic islets of mice. Endocrinology 1967, 81:105-112.
12. Vara E, Tamarit-Rodriguez J: Glucose stimulation of insulin secretion in islets of fed and starved rats and its dependence on lipid metabolism. Metab Clin Exp 1986, 35:266-271.
13. Malaisse WJ: Insulin secretion: Multifactorial regulation for a single process of release. Diabetologia 1973, 9:167-173.
14. Carpinelli AR, Curi R, Malaisse WJ: Long-term regulation of pancreatic B-cell responsiveness to D-glucose by food availability, feeding schedule and diet composition. Physiol Behav 1992, 52:1193-1196.
15. Newgard CB, McGarry JD: Metabolic coupling factors in pancreatic β cell signal transduction. Annu Rev Biochem 1995, 64:689-719.
16. Warnotte C, Gilon P, Nenquin M, Henquin JC: Mechanisms of the stimulation of insulin release by saturated fatty acids: a study of palmitate effects in mouse β-cells. Diabetes 1994, 43:703-711.
17. Stein DT, Esser V, Stevenson BE, Lane KE, Whiteside JH, Daniels MB, Chen S, McGarry JD: Essentially of circulating fatty acids for glucose-stimulated insulin secretion in fasted rats. J Clin Invest 1996, 97:2728-2735.
18. McGarry JD, Dobbins RL: Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999, 42:128-138.
19. Hamilton JA, Civelek VN, Kamp F, Tornheim K, Corkey BE: Changes in internal pH caused by movement of fatty acids into and out of clonal pancreatic β-cells (HIT). J Biol Chem 1994, 269:20852-20856.
20. Matschinsky FM: A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 1996, 45:223-241.
21. McGarry JD: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002, 51:7-18.
22. Berne C: The metabolism of lipid in mouse pancreatic islets. The biosynthesis of triacylglycerols and phospholipids. Biochem J 1975, 152:667-673.
23. Boylan JG, Hamilton JA: Interactions of acyl-coenzyme A with phosphatidylcholine bilayers and serum albumin. Biochemistry 1992, 31:557-567.
24. Corkey B: Analysis of acyl-coenzyme A esters in biological samples. Methods Enzymol 1988, 166:55-70.
25. Mason TM, Goh T, Tchipashvili V, Sandhu H, Gupta N, Lewis GF, Giacca A: Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats. Diabetes 1999, 48:524-530.
26. Unger RH: How obesity causes diabetes in Zucker diabetic fatty rats. Trends Endocrinol Metab 1997, 7:276-282.
27. Carpentier A, Mittelman SD, Lamarche B, Bergman RN, Giacca A, Lewis GF: Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. Am J Physiol 1999, 276:E1055-E1066.
28. Carpentier A, Mittelman SD, Bergman RN, Giacca A, Lewis GF: Prolonged elevation of plasma free fatty acids impairs pancreatic B-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. Diabetes 2000, 49:399-408.
29. Kashyap SR, Belfort R, Berria R, Suraamornkul S, Pratipranawatr T, Finlayson J, Barrentine A, Bajaj M, Mandarino L, DeFronzo R, Cusi K: Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. Am J Physiol Endocrinol Metab 2004, 287:E537-E546.
30. Paolisso G, Gambardella A: Opposite effects of short and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia 1995, 38:1295-1299.
31. Stefan N, Fritsche A, Haring H, Stumvoll M: Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12 Ala polymorphism of the peroxisome proliferator-activated receptor γ2 gene. Diabetes 2001, 50:1143-1148.
32. Paolisso G, Tagliamonte MR, Rizzo MR, Gualdiero P, Saccomanno F, Gambardella A, Giugliano D, D'Onofrio F, Howard BV: Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes. Diabetologia 1998, 41:1127-1132.
33. Qvigstad E, Mostad IL, Bjerve KS, Grill VE: Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects. AM J Physiol Endocrinol Metab 2003, 284:E129-E137.
34. Unger RH: Lipotoxic diseases. Annu Rev Med 2002, 53:319-336.
35. Shimabukuro M, Zhou YT, Levi M, Unger RH: Fatty acid induced β-cell apoptosis: a link between diabetes and obesity. Proc Natl Acad Sci USA 1998, 95:2498-2502.
36. Lupi R, Dotta F, Marselli L, Del Guerra S, Masini M, Santangelo C, Patane G, Boggi U, Piro S, Anello M, Bergamini E, Mosca F, Di Mario U, Del Prato S, Marchetti P: Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: Evidence that cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 2002, 51:1437-1442.
37. Kersten S: Effects of fatty acids on gene expression: role of peroxisome proliferator-activated receptor α, liver X receptor α and sterol regulatory element-binding protein-1 c. Proc Nutr Soc 2002, 61:371-374.
38. Reddy JK, Chu R: Peroxisome proliferator-induced pleiotropic responses: Pursuit of a phenomenon. Ann NY Acad Sci 1996, 804:176-201.
39. Goldfischer SL: Peroxisomal diseases. Prog Clin Biol Res 1988, 282:117-137.
40. Rosen ED, Spiegelman BM: PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001, 276:37731-37734.
41. Sher T, Yi H-F, McBride OW, Gonzalez FJ: cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 1993, 32:5598-5604.
42. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator activated receptor (PPARs): tissue distribution of PPAR-α, -β and -γ in the adult rat. Endocrinology 1996, 137:354-366.
43. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Staels B, Auwerx J, Laville M, Vidal H: Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor α in humans. Diabetes 1997, 46:1319-1327.
44. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B: Activation of proliferatoractivated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998, 273:25573-25580.
45. Inoue I, Shino K, Noji S, Awata T, Katayama S: Expression of peroxisome proliferator-activated receptor α in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 1998, 246:370-374.
46. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A: Activation of human aortic smooth-muscle cells is inhibited by PPARα but not PPARγ activators. Nature 1998, 393:790-793.
47. Gottlicher M, Widmark E, Li Q, Gustafsson JA: Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 1992, 89:4653-4657.
48. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J: Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγ activators. J Biol Chem 1997, 272:28210-28217.
49. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W: Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992, 68:879-887.
50. Kersten S: Peroxisome proliferator activated receptors and obesity. Eur J Pharmacol 2002, 440:223-234.
51. Issemann I, Green S: Activation of a member of the steroid hormone receptor superfamily by some peroxisome proliferators. Nature 1990, 347:645-649.
52. Cattley RC, DeLuca J, Elcombe C, Fenner-Crisp P, Lake BG, Marsman DS, Pastoor TA, Popp JA, Robinson DE, Schwetz B, Tugwood J, Wahli W: Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul Toxicol Pharmacol 1998, 27:47-60.
53. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999, 20:649-688.
54. Verges B: Clinical interest of PPAR ligands. Particular benefit in type 2 diabetes and metabolic syndrome. Diabetes Metab 2004, 30:7-12.
55. Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA: Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acid. Mol Endocrinol 1992, 6:1634-1641.
56. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 1994, 91:7355-7359.
57. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B: Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001, 142:4195-4202.
58. Bastie C, Holst D, Gaillard D, Jehl-Pietri C, Grimaldi PA: Expression of peroxisome proliferator-activated receptor PPARδ promotes induction of PPARγ and adipocyte differentiation in 3T3C2 fibroblasts. J Biol Chem 1999, 274:21920-21925.
59. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA, Milburn MV: Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 1999, 3:397-403.
60. Gaw A, Packard CJ, Shepherd J: Fibrates. Handb Exp Pharmacol 1994, 109:325-48.
61. Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P, Muscat GE: The peroxisome proliferator-activated receptor β/δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol 2003, 17:2477-2493.
62. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA: Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 2000, 101:1311-1318.
63. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ: The nuclear receptor PPARγ and immunoregulation. PPARγ mediates inhibition of helper T cell responses. J Immunol 2000, 164:1364-1371.
64. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM: PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999, 4:611-617.
65. Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, Spiegelman B, Flier JS, Moller DE: Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest 1996, 97:2553-61.
66. Tontonoz P, Hu E, Spiegelman BM: Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor γ. Curr Opin Genet Dev 1995, 5:571-576.
67. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J: Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPAR α and PPAR γ activators. J Biol Chem 1997, 272:28210-28217.
68. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998, 101:1354-1361.
69. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
70. Walczak R, Tontonoz P: PPARadigms and PPARadoxes: expanding roles for PPAR γ in the control of lipid metabolism. J Lipid Res 2002, 43:177-186.
71. Kallen CB, Lazar MA: Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 1996, 93:5793-5796.
72. De Vos P, Lefebvre AM, Miller SG, Guerre-Millo M, Wong KM, Saladin R, Hamann LG, Staels B, Briggs MR, Auwerx J: Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ. J Clin Invest 1996, 98:1004-1009.
73. Jiang C, Ting AT, Seed B: PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
74. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP: Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998, 95:8806-8811.
75. Gimble JM, Pighetti GM, Lerner MR, Wu X, Lightfoot SA, Brackett DJ, Darcy K, Hollingsworth AB: Expression of peroxisome proliferator-activated receptor mRNA in normal and tumorigenic mammary glands. Biochem Biophys Res Commun 1998, 253:813-817.
76. Zhou Y-T, Shimabukuro M, Wang M-Y, Lee Y, Higa M, Milburn JL, Newgard CB, Unger RH: Role of peroxisome proliferator-activated receptor α in disease of pancreatic β cells. Proc Natl Acad Sci USA 1998, 95:8898-8903.
77. Dubois M, Paltou F, Kerr-Conte J, Gyr V, Vandewalle B, Desreumaux P, Auwerx J, Schoonjans K, Lefebvre J: Expression of peroxisome proliferator-activated receptor γ in normal human pancreatic islet cells. Diabetologia 2000, 43:1165-1169.
78. ATP channels and induce insulin secretion. J Pharmacol Exp Ther 2004, 310:1273-1280.
79. Roduit R, Morin J, Masse F, Segall L, Roche E, Newgard CB, Assimacopoulos-Jeannet F, Prentki M: Glucose down-regulates the expression of the peroxisome proliferator-activated receptor-α gene in the pancreatic β-cell. J Biol Chem 2000, 275:35799-35806.
80. Laybutt R, Hasenkamp W, Groff A, Grey S, Jonas JC, Kaneto H, Sharma A, Bonner-Weir S, Weir G: Beta-cell adaptation to hyperglycemia. Diabetes 2001, 50(Suppl 1):S180-S181.
81. Yoshikawa H, Tajiri Y, Sako Y, Hashimoto T, Umeda F, Nawata H: Effects of free fatty acids on beta-cell functions: a possible involvement of peroxisome proliferator-activated receptors alpha or pancreatic/duodenal homeobox. Metabolism 2001, 50:613-618.
82. Sugden MC, Bulmer K, Augustine D, Holness MJ: Selective modification of pyruvate dehydrogenase kinase isoform expression in rat pancreatic islets elicited by starvation and activation of peroxisome proliferator-activated receptor-α: implications for glucose-stimulated insulin secretion. Diabetes 2001, 50:2729-2736.
83. Sugden MC, Holness MJ: Potential role of peroxisome proliferator- activated receptor-α in the modulation of glucose-stimulated insulin secretion. Diabetes 2004, 53(Suppl 1):S71-S81.
84. Guerre-Millo M, Rouault C, Poulain P, Andre J, Poitout V, Peters JM, Gonzalez FJ, Fruchart JC, Reach G, Staels B: PPAR-α-null mice are protected from high-fat diet-induced insulin resistance. Diabetes 2001, 50:2809-2814.
85. Sugden MC, Bulmer K, Gibbons GF, Knight BL, Holness MJ: Peroxisome-proliferator-activated receptor-α (PPARα) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin. Biochem J 2002, 364:361-368.
86. Kersten S, Mandard S, Escher P, Gonzalez FJ, Tafuri S, Desvergne B, Wahli W: The peroxisome proliferator-activated receptor alpha regulates amino acid metabolism. FASEB J 2001, 15:1971-1978.
87. Maechler P, Wollheim CB: Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis. Nature 1999, 402:685-689.
88. Unger RH, Orci L: Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 2002, 1585:202-212.
89. Prentki M, Joly E, El-Assaad W, Roduit R: Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity. Role in β-cell adaptation and failure in the etiology of diabetes. Diabetes 2002, 51(Suppl 3):S405-S413.
90. Tordjman K, Standley KN, Bernal-Mizrachi C, Leone TC, Coleman T, Kelly DP, Semenkovich CF: PPARα suppresses insulin secretion and induces UCP2 in insulinoma cells. J Lipid Res 2002, 43:936-943.
91. Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S, Stannard B, Heron-Milhavet L, Wheeler MB, LeRoith D: Peroxisome proliferator-activated receptor-α agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 2003, 52:1770-1778.
92. Koh EH, Kim M-S, Park J-Y, Kim HS, Youn J-Y, Park H-S, Youn JH, Lee K-U: Peroxisome proliferator-activated receptor (PPAR)-α activation prevents diabetes in OLETF rats. Comparison with PPAR-γ activation. Diabetes 2003, 52:2331-2337.
93. Kelly LJ, Vicario PP, Thompson GM, Candelore MR, Doebber TW, Ventre J, Wu MS, Meurer R, Forrest MJ, Conner MW, Cascieri MA, Molle DE: Peroxisome proliferator-acitvated receptors γ and α mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression. Endocrinology 1998, 139:4920-4927.
94. Schrauwen P, Hesselink M: UCP2 and UCP3 in muscle controlling body metabolism. J Exp Biol 2002, 205:2275-85.
95. Grav HJ, Tronstad KJ, Gudbrandsen OA, Berge K, Fladmark KE, Martinsen TC, Waldum H, Wergedahl H, Berge RK: Changed energy state and increased mitochondrial beta-oxidation rate in liver of rats associated with lowered proton electrochemical potential and stimulated uncoupling protein 2 (UCP-2) expression: evidence for peroxisome proliferator-activated receptor-alpha independent induction of UCP-2 expression. J Biol Chem 2003, 278(33):30525-33.
96. Chan CB, De Leo D, Joseph JW, McQuaid TS, Ha XF, Xu F, Tsushima RG, Pennefather PS, Salapatek AM, Wheeler MB: Increased uncoupling protein-2 levels in beta cells are associated with impaired glucose-stimulated insulin secretion: mechanism of action. Diabetes 2001, 50:1302-1310.
97. Hong Y, Fink BD, Dillon JS, Sivitz W: Effects of adenoviral over-expression of uncoupling protein-2 and -3 on mitochondrial respiration in insulinoma cells. Endocrinology 2001, 142:249-56.
98. Zhang CY, Baffy G, Perret P, Krauss S, Peroni O, Grujic D, Hagen T, Vidal-Puig AJ, Boss O, Kim YB, Zheng XX, Wheeler MB, Shulman GI, Chan CB, Lowell BB: Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction and type 2 diabetes. Cell 2001, 105:745-55.
99. Joseph JW, Koshkin V, Zhang CY, Wang J, Lowell BB, Chan CB, Wheeler MB: Uncoupling protein 2 knockout mice have enhanced insulin secretory capacity after a high fat diet. Diabetes 2002, 51:3211-3219.
100. Patane G, Anello M, Piro S, Vigneri R, Purrello F, Rabuazzo AM: Role of ATP production and uncoupling protein-2 in the insulin secretory defect induced by chronic exposure to high glucose or free fatty acids and effects of peroxisome proliferator-activated receptor-γ inhibition. Diabetes 2002, 51:2749-2756.
101. Shimabukuro M, Zhou Y-T, Lee Y, Unger RH: Induction of uncoupling protein-2 mRNA by troglitazone in the pancreatic islets of Zucker diabetic fatty rats. Biochem Biophys Res Commun 1997, 237:359-361.
102. Sreenan S, Sturis J, Pugh W, Burant CF, Polonsky KS: Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am J Physiol 1996, 271:E742-E747.
103. Parton LE, Diraison F, Neill SE, Ghosh SK, Rubino MA, Bisi JE, Briscoe CP, Rutter GA: Impact of PPARγ overexpression and activation on pancreatic islet gene expression profile analyzed with oligonucleotide microarrays. Am J Physiol Endocrinol Metab 2004, 287:E390-E404.
104. Yajima K, Hirose H, Fujita H, Seto Y, Fujita H, Ukeda K, Miyashita K, Kawai T, Yamamoto Y, Ogawa T, Yamada T, Saruta T: Combination therapy with PPARγ and PPARα agonists increases glucosestimulated insulin secretion in db/db mice. Am J Physiol Endocrinol Metab 2003, 284:E966-E791.
105. Eto K, Yamashita T, Matsui J, Terauchi Y, Noda M, Kadowaki T: Genetic manipulation of fatty acid metabolism in β-cells are associated with dysregulated insulin secretion. Diabetes 2002, 51(Suppl 3):S414-S420.
106. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Nagai R, Tobe K, Kimura S, Kadowaki T: PPAR-γ mediates high-fat dietinduced adipocyte hypertrophy and insulin resistance. Mol Cell 1999, 4:597-609.
107. Kim HI, Cha JY, Kim SY, Kim JW, Roh KJ, Seong JK, Lee NT, Choi KY, Kim KS, Ahn YH: Peroxisomal proliferator-activated receptor-gamma upregulates glucokinase gene expression in beta-cells. Diabetes 2002, 51:676-685.
108. Kim HI, Kim JW, Kim SH, Cha JY, Kim AS, Ahn YH: Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter. Diabetes 2000, 49:1517-1524.
109. Wang Z, Gleichmann H: Glut2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes 1998, 47:50-56.
110. Nakamichi Y, Kikuta T, Ito E, Ohara-Imaizumi M, Nishiwaki C, Ishida H, Nagamatsu S: PPAR-γ overexpression suppresses glucose-induced proinsulin biosynthesis and insulin release synergistically with pioglitazone in MIN6 cells. Biochem Biophys Res Commun 2003, 306:832-836.
111. Lupi R, Del Guerra S, Marselli L, Bugliani M, Boggi U, Mosca F, Marchetti P, Del Prato S: Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARγ2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 2003, 286:E560-E567.
112. Ishida H, Takizawa M, Ozawa S, Nakamichi Y, Yamaguchi S, Katsuta H, Tanaka T, Maruyama M, Katahira H, Yoshimoto K, Itagaki E, Nagamatsu S: Pioglitazone improves insulin secretory capacity and prevents the loss of β-cell mass in obese diabetic db/db mice: possible protection of β-cells from oxidative stress. Metabolism 2004, 53:488-494.
113. Diani AR, Sawada G, Wyse B, Marray FT, Khan M: Pioglitazone preserves pancreatic islet structure and insulin secretory funciton in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab 2003, 286:E116-E122.
114. Higa M, Zhou Y-T, Ravazzola M, Baetens D, Orci L, Unger RH: Troglitazone prevents mitochondrial alterations, β cell destruction and diabetes in obese prediabetic rats. Proc Natl Acad Sci USA 1999, 96:11513-11518.
115. Beales PE, Liddi R, Giorgini AE, Signore A, Procaccini E, Batchelor K, Pozzilli P: Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse. Eur J Pharmacol 1998, 357:221-225.
116. Pershadsingh HA: Peroxisome proliferator-activated receptor-γ: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin Investig Drugs 2004, 13:215-228.
117. Rosen ED, Kulkarni RN, Sarraf P, Ozcan U, Okada T, Hsu C-H, Eisenman D, Magnuson MA, Gonzalez FJ, Kahn CR, Spiegelman BM: Targeted elimination of peroxisome proliferator-activated receptor γ in β cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol Cell Biol 2003, 23:7222-7229.
118. Foufelle F, Ferre P: New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J 2002, 366:377-391.
119. Horton JD, Goldstein JL, Brown MS: SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002, 109:1125-1131.
120. Kakuma T, Lee Y, Higa M, Wang Z, Pan W, Shimomura I, Unger RH: Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc Natl Acad Sci USA 2000, 97:8536-8541.
121. Andreolas C, da Silva Xavier G, Diraison F, Zhao C, Varadi A, Lopez-Casillas F, Ferre P, Foufelle F, Rutter GA: Stimulation of acetyl-CoA carboxylase gene expression by glucose requires insulin release and sterol regulatory element binding protein 1c in pancreatic MIN6 beta-cells. Diabetes 2002, 51:2536-2545.
122. Wang H, Maechler P, Antinozzi PA, Herrero L, Hagenfeldt-Johansson KA, Bjorklund A, Wollheim CB: The transcription factor SREBP-1c is instrumental in the development of beta-cell dysfunction. J Biol Chem 2003, 278:16622-16629.
123. Diraison F, Parton L, Ferre P, Foufelle F, Briscoe CP, Leclerc I, Rutter GA: Over-expression of sterol-regulatory-element-binding protein-1c (SREBP1c) in rat pancreatic islets induces lipogenesis and decreases glucose-stimulated insulin release: modulation by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR). Biochem J 2004, 378:769-778.
124. Medvedev AV, Robidoux J, Bai X, Cao W, Floering LM, Daniel KW, Collins S: Regulation of the uncoupling protein-2 gene in INS-1 β-cells by oleic acid. J Biol Chem 2002, 277:42639-42644.
125. Yamashita T, Eto K, Okazaki Y, Yamashita S, Yamauchi T, Sekine N, Nagai R, Noda M, Kadowaki T: Role of uncoupling protein-2 upregulation and triglyceride accumulation in impaired glucose-stimulated insulin secretion in a β-cell lipotoxicity model overexpressing sterol regulatory element binding protein-1c. Endocrinology 2004, 145:3566-3577.
126. Poitout V: β-cell lipotoxicity: burning fat into heat? Endocrinology 2004, 145:3563-3565.
127. Elholm M, Bjerking G, Knudsen J, Kristiansen K, Mandrup S: Regulatory elements in the promoter region of the rat gene encoding the acyl-CoA-binding protein. Gene 1996, 173:233-238.
128. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W: The PPARα-leukotriene B4 pathway to inflammation control. Nature 1996, 384:39-43.
129. Varanasi U, Chu R, Huang Q, Castellon R, Yeldandi AV, Reddy JK: Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. J Biol Chem 1996, 271:2147-2155.
130. Karam WG, Ghanayem BI: Induction of replication DNA synthesis and PPARα-dependent gene transcription by Wy-14643 in primary rat hepatocyte and non-parenchymal cell co-cultures. Carcinogenesis 1997, 18:2077-2083.
131. Berthou L, Duverger N, Emmanuel F, Langouet S, Auwerx J, Guillouzo A, Fruchart JC, Rubin E, Denefle P, Staels B, Branellec D: Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 1996, 97:2408-2416.
132. Raspe E, Madsen L, Lefebvre AM, Leitersdorf I, Gelman L, Peinado-Onsurbe J, Dallongeville J, Fruchart JC, Berge R, Staels B: Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARα activation. J Lipid Res 1999, 40:2099-2110.
133. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JC, Staels B, Auwerx J: Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 1995, 96:741-750.
134. Prieur X, Coste H, Rodriguez JC: The human apolipoprotein AV gene is regulated by PPAR α and contains a novel FXR response element. J Biol Chem 2003, 278:25468-25480.
135. Hertz R, Bishara-Shieban J, Bar-Tana J: Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem 1995, 270:13470-13475.
136. Nicolas-Frances V, Dasari VK, Abruzzi E, Osumi T, Latruffe N: The peroxisome proliferator response element (PPRE) present at positions-681/-669 in the rat liver 3-ketoacyl-CoA thiolase B gene functionally interacts differently with PPARα and HNF-4. Biochem Biophys Res Commun 2000, 269:347-351.
137. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W: Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J Clin Invest 1999, 103:1489-1498.
138. Leone TC, Weinheimer CJ, Kelly DP: A critical role for the peroxisome proliferator-activated receptor α in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 1999, 96:7473-7478.
139. Aoyama T, Peters JM, Iritani N, Nakajuima T, Furihata K, Hashimoto T, Gonzalez FJ: Altered constitutive expression of fatty acidmetabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α. J Biol Chem 1998, 273:5678-5684.
140. Minnich A, Tian N, Byan L, Bilder G: A potent PPARα agonist stimulates mitochondrial fatty acid β-oxidation in liver and skeletal muscle. Am J Physiol Endocrinol Metab 2001, 280:E270-E279.
141. Kroetz DL, Yook P, Costet P, Bianchi P, Pineau T: Peroxisome proliferator-activated receptor α controls the hepatic CYP4A induction adaptive response to starvation and diabetes. J Biol Chem 1998, 273:31581-31589.
142. Aldridge TC, Tugwood JD, Green S: Identification and characterization of DNA elements implicated in the regulation of CYP4A1 transcription. Biochem J 1995, 306:473-479.
143. Yu S, Cao WQ, Kashireddy P, Meyer K, Jia Y, Hughes DE, Tan Y, Feng J, Yeldandi AV, Rao MS, Costa RH, Gonzalez FJ, Reddy JK: Human peroxisome proliferator-activated receptor α supports the induction of peroxisome proliferation in PPARα-deficient mouse liver. J Biol Chem 2001, 276:42485-42491.
144. Patel DD, Knight BL, Soutar AK, Gibbons GF, Wade DP: The effect of peroxisome-proliferator-activated receptor-α on the activity of the cholesterol 7 α-hydroxylase gene. Biochem J 2000, 351:747-753.
145. Cheema SK, Agellon LB: The murine and human cholesterol 7 α-hydroxylase gene promoters are differentially responsive to regulation by fatty acids mediated via peroxisome proliferator-activated receptor α. J Biol Chem 2000, 275:12530-12536.
146. Guillou H, Martin P, Jan S, D'Andrea S, Roulet A, Catheline D, Rioux V, Pineaut T, Legrand P: Comparative effect of fenofibrate on hepatic desaturases in wild-type and peroxisome proliferator-activated receptor α-deficient mice. Lipids 2002, 37:981-989.
147. Wolfrum C, Ellinghaus P, Fobker M, Seedorf U, Assmann G, Borchers T, Spener F: Phytanic acid is ligand and transcriptional activator of muring liver fatty acid binding protein. J Lipid Res 1999, 40:708-714.
148. Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N: Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue- and inducer-specific manner. J Biol Chem 1998, 273:16710-16714.
149. Yamazaki K, Kuromitsu J, Tanaka I: Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator-activated receptor α agonists. Biochem Biophys Res Commun 2002, 290:1114-1122.
150. Kok T, Wolters H, Bloks W, Havinga R, Jansen PL, Staels B, Kuipers F: Induction of hepatic ABC transporter expression is part of the PPARα-mediated fasting response in the mouse. Gastroenterology 2003, 124:160-171.
151. Tobin KA, Steineger HH, Alberti S, Spydevold O, Auwerx J, Gustafsson JA, Nebb HI: Cross talk between fatty acid and cholesterol metabolism mediated by liver X receptor-α. Mol Endocrinol 2000, 14:741-752.
152. Hsu MH, Savas U, Griffin KJ, Johnson EF: Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor α in HepG2 cells. J Biol Chem 2001, 276:27950-27958.
153. Shin M, Ohnishi M, Iguchi S, Sano K, Umezawa C: Peroxisome-proliferator regulates key enzymes of the tryptophan-NAD+ pathway. Toxicol Appl Pharmacol 1999, 158:71-80.
154. Wan YJ, Cai Y, Lungo W, Fu P, Locker J, French S, Sucov HM: Peroxisome proliferator-activated receptor a-mediated pathways are altered in hepatocyte-specific retinoid X receptor a-deficient mice. J Biol Chem 2000, 275:28285-28290.
155. Hegardt FG: Transcriptional regulation of mitochondrial HMG-CoA synthase in the control of ketogenesis. Biochimie 1998, 80:803-806.
156. Bouly M, Masson D, Gross B, Jiang XC, Fievet C, Castro G, Tall AR, Fruchart JC, Staels B, Lagrost L, Luc G: Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. J Biol Chem 2001, 276:25841-25847.
157. Miller CW, Ntambi JM: Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression. Proc Natl Acad Sci USA 1996, 93:9443-9448.
158. Yoo HY, Chang MS, Rho HM: Induction of the rat Cu/Zu superoxide dismutase gene through the peroxisome proliferatorresponsive element by arachidonic acid. Gene 1999, 234:87-91.
159. Latruffe N, Nicolas-Frances V, Dasari VK, Osumi T: Studies on regulation of the peroxisomal beta-oxidation at the 3-ketothiolase step. Dissection of the rat liver thiolase B gene promoter. Adv Exp Med Biol 1999, 466:253-259.
160. Hertz R, Seckbach M, Zakin MM, Bar-Tana J: Transcriptional suppression of the transferrin gene by hypolipidemic peroxisome proliferators. J Biol Chem 1996, 271:218-224.